MTAPWVALALLWGSLWPGSGRGEAETRECIYYNANWELER
TNQSGLERCEGEQDKRLHCYASW(A/R)NSSGTIELVKKG
CWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHL
PEAGGPEVTYEPPPTAPTGGGGSVDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
LSPGK
(SEQ ID NO: 98)

Fig. 1

MTAPWVALALLWGSLWPGSGRGEAETRECIYYNANWELER
TNGSGLERCEGEQDKRLHCYASW(A/R)NSSGTIELVKKG
CWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHL
PEAGGPEGPWASTTIPSGGPEATAAAGDQGSGALWLCLEGP
AHEGGGGSVDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYLTTPPVLDSDGSFFLYSKLTVDKS
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
(SEQ ID NO: 99)

Fig. 2



Testis Mass (g)
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
WT + Veh.
KO + Veh.
KO + E28W

Fig. 3A



Ovary Mass (g)
0.20
0.15
0.10
0.05
0.00
WT + Veh.
KO + Veh.
KO + E28W

Fig. 3B



Treatment: 10 mg/kg, SC, 1X/wk
% Survival
Mice Age (days)
WT + Veh. (n=19)
KO + Veh. (n=26)
KO + E28W. (n=25)
0
10
20
30
40
50
60
70
80
90
100
110
0
25
50
75
100
125
150

Fig. 4A



Treatment: 10 mg/kg, SC, 1X/wk
% Survival
Mice Age (days)
WT + Veh. (n=17)
KO + Veh. (n=23)
KO + E28W. (n=22)
0
10
20
30
40
50
60
70
80
90
100
110
0
25
50
75
100
125
150
175
200

Fig. 4B



30
28
26
24
22
20
18
Body Weight (g)
n=17
n=10
n=3
Dosing
0
5
10
15
20
25
30
35
Days after Tumor Implantation
N + V(n=10)
C26 + E28W (n=20)
C26 + V(n=20)

Fig. 5



Survival Rate (%)
100
90
80
70
60
50
40
30
20
10
0
0
5
10
15
20
25
30
35
Days after Tumor Implantation
C-26 + V (n=20)
C-26 + E28W (n=20)
N + V (n=10)

Fig. 6



***
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
ActivIn A (pg/ml)
Normal
OC

Fig. 7A



WT + PBS
KO + PBS
KO + sActRIIB
***
Activin A (pg/ml)
70000
60000
50000
40000
30000
20000
10000
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Treatment (Day)

Fig. 7B



WT + PBS
KO + PBS
KO + sActRIIB
***
Ovary Mass (g)
0.0
0.1
0.2
0.3
0.4
0.5
Treatment (Day)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Fig. 7C




Fig. 7D



WT + Veh
KO + Veh
KO + E28W
*
*
VEGF (pg/ml)
600
500
400
300
200
100
0
WT + PBS
KO + PBS
KO + sActRIIB

Fig. 8A



Active Caspase-3
**
Positive Cells /mm²
30
25
20
15
10
5
0
KO + PBS
KO + sActRIIB
KO + PBS
KO + sActRIIB

Fig. 8B



TOV-21G + PBS
TOV-21G + sActRIIB
TOV-21G + 5-FU
TOV-21G + sActRIIB + 5-FU
↓34% ***
↓49% ***
↓74% ***
Tumor volume (mm3)
Days Post Tumor Implantation
0
200
400
600
800
1000
1200
1400
10
20
30
40
50
60

Fig. 9A



Tumor Volume (mm3)
275
250
225
200
175
150
125
100
75
50
25
0
17
18
19
20
21
22
23
24
25
26
27
Days post implantation
*
*
*
G361 + PBS
G361 + Dacarbazine
G361 + sActRIIB
G361 + sActRIIB + Dacarbazine

Fig. 9B